Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Virchows Archiv : an International Journal of Pathology|July 22, 2018
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendationsG W van Pelt, S Kjær-Frifeldt, J H J M van Krieken, et al.
International Journal of Cancer|March 30, 2011
Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomasA Middeldorp, R van Eijk, J Oosting, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 15, 2001
Caspase-3 activity as a prognostic factor in colorectal carcinomaL E Jonges, J F Nagelkerke, N G Ensink, et al.
Genes, Chromosomes & Cancer|October 5, 2023
Colibactin mutational signatures in NTHL1 tumor syndrome and MUTYH associated polyposis patientsD Terlouw, A Boot, Q R Ducarmon, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 12, 2005
The feasibility and reliability of sentinel node mapping in colorectal cancerF S Doekhie, K C M J Peeters, P J K Kuppen, et al.
Clinical Genetics|May 11, 2007
Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposisM Nielsen, F J Hes, F M Nagengast, et al.
The Journal of Pathology|October 31, 2000
Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patientsW J de Leeuw, J Dierssen, H F Vasen, et al.
Journal of Clinical Pathology|September 1, 2006
Duodenal carcinoma in MUTYH-associated polyposisM Nielsen, J W Poley, S Verhoef, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2016
Practical guidance for mismatch repair-deficiency testing in endometrial cancerE Stelloo, A M L Jansen, E M Osse, et al.
International Journal of Endocrinology|August 22, 2015
Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II TrialT C Schneider, D de Wit, T P Links, et al.
Pageof 7